Nation
World
Politics
Sports
Business
Entertainment
Life
Tech
Science
Opinion
Crime
Health
Oddities

Lilly loses $120 billion in value as rival obesity drugs impress

Por: The Boston Globe Business July 26, 2024

thumbnail

Eli Lilly & Co. is down more than $120 billion in market value and its status as the poster child of the weight-loss drug frenzy is under threat with at least two rivals posting encouraging developments for their obesity treatments.The company’s shares fell as much as 6.2 percent on Thursday, hitting the lowest intraday level since May. They’re down 14 percent over the past eight trading sessions, their worst eight-day stretch since 2020.New... + full article



Similar News

Health care advocates develop first-ever 'Obesity Bill of Rights'

WPTV USA Nation February 01, 2024

thumbnailHealth care advocates introduced what they call the first-ever  with the hopes of changing workplace policies and state and federal laws. The Obesity Bill of Rights, which was published Wednesday by the National Consumers League and National Council on Aging, has the backing... + más

Did Martha Washington really name a cat after Alexander Hamilton? | The Boston Globe

'Frustration' fuels Broncos' sideline blowup in loss | ESPN


Eli Lilly broadens access to weight loss drugs with new website

Fox Business USA Business January 04, 2024

thumbnail Beachbody co-founder and CEO Carl Daikeler explains how the popularity of weight loss drugs is impacting online fitness subscriptions on 'The Claman Countdown.' became the latest in a growing number of companies making it even easier for patients to gain access to... + más

FDA approves a new weight loss drug, Zepbound from Eli Lilly | CBS News

As Eli Lilly Gears Up For Growth, Its CFO Prescribes Leading Indicators | Forbes


Five obesity-drug trends to watch in 2024: Who can compete with Eli Lilly and Novo Nordisk? 

MarketWatch USA Business December 23, 2023

thumbnailKey clinical-trial data emerging over the next year “will really start to dictate who will be the competitors against Lilly and Novo,” said Damien Conover, director of healthcare research at Morningstar.  While new, next-generation obesity drugs aren’t likely to hit the... + más

NFL Playoff Scenarios | ABC News

Eli Lilly, Novo Nordisk test popular weight loss-related drugs on children | Fox Business


Obesity in 2035 could be just as costly as COVID in 2020

WPTV USA Nation March 04, 2023

thumbnailThe global economic impact of obesity in 2035 is expected to be comparable to that of COVID-19 in 2020, according to a new report by the World Obesity Federation. half of the world’s population will either be considered overweight or obese by 2035. Even more concerning,... + más

Half Of Global Population Will Be Overweight In 12 Years: Study | RTTNews

‘Worrying’ global obesity projections for 2035 revealed in new report | New York Post


Half Of Global Population Will Be Overweight In 12 Years: Study

RTTNews USA Health March 03, 2023

thumbnailMore than half the global population will be living with overweight and obesity within 12 years if prevention, treatment and support do not improve, says a global study conducted by the World Obesity Federation.The World Obesity Atlas 2023, published ahead of World Obesity Day,... + más

World’s fattest countries revealed: Where does America fall on the list? | New York Post

‘Worrying’ global obesity projections for 2035 revealed in new report | New York Post


The End Of Obesity

Forbes USA Tech January 25, 2023

thumbnailSince its launch in 2021, Novo Nordisk’s weight loss drug, Wegovy, set the stage for the next ... [+] generation of anti-obesity drugs. Now a new drug on the scene promises to be more effective and safer than any other weight loss drug before.getty Obesity remains one of the... + más

New guidance: Use drugs, surgery early for obesity in kids | ABC News

Use drugs and surgery early for obesity in kids, new guidance says | Orlando Sentinel


As Eli Lilly Gears Up For Growth, Its CFO Prescribes Leading Indicators

Forbes USA Business December 15, 2022

thumbnailAlong the corridors of Indianapolis-based Eli Lilly, NBP may not have the brand swagger of Trulicity or Mounjaro, but as the drugmaker eyes a rich menu of growth opportunities, the sturdy acronym promises to be a powerful pain reliever. Or so Lilly CFO Anat Ashkenazi explains,... + más

Twitter was once a necessity for major brands. Under Elon Musk, it's now high risk. | CBS News

A fake tweet sparked panic at Eli Lilly and may have cost Twitter millions | Portland Press Herald



About iurex | Privacy Policy | Disclaimer |